186 related articles for article (PubMed ID: 33224753)
1. Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study.
Liu Z; Xie Q; Xiang Q; Zhang H; Mu G; Zhao Z; Hu T; Wu T; Wang N; Zhang J; Qian Y; Zhou S; Wang Z; Jiang J; Zhang Y; Song H; Cui Y
Cardiovasc Diagn Ther; 2020 Oct; 10(5):1293-1302. PubMed ID: 33224753
[TBL] [Abstract][Full Text] [Related]
2. Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
Liu Z; Zhang H; Xie Q; Mu G; Zhou S; Wang Z; Wang Z; Jiang J; Xiang Q; Cui Y
Clin Ther; 2020 Oct; 42(10):2066-2081.e9. PubMed ID: 32900534
[TBL] [Abstract][Full Text] [Related]
3. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
Lippi G; Favaloro EJ
Clin Chem Lab Med; 2015 Feb; 53(2):185-97. PubMed ID: 25241734
[TBL] [Abstract][Full Text] [Related]
4. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
Liu Z; Xie Q; Zhang H; Mu G; Zhou S; Wang Z; Jiang J; Xiang Q; Cui Y
Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Terayama Y
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097
[TBL] [Abstract][Full Text] [Related]
6. International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study.
Ofek F; Barchel D; Perets N; Ziv-Baran T; Mahajna A; Filipovich-Rimon T; Garach-Jehoshua O; Berlin M; Berkovitch M
Front Pharmacol; 2019; 10():1177. PubMed ID: 31649541
[No Abstract] [Full Text] [Related]
7. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
[TBL] [Abstract][Full Text] [Related]
9. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
[TBL] [Abstract][Full Text] [Related]
10. [Direct Oral Anticoagulants (DOACs): Pharmacological Characteristics and Laboratory Assessment].
Kitajima I
Rinsho Byori; 2016 Aug; 64(8):972-979. PubMed ID: 30609341
[TBL] [Abstract][Full Text] [Related]
11. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
13. Viscoelastometry for detecting oral anticoagulants.
Groene P; Wagner D; Kammerer T; Kellert L; Giebl A; Massberg S; Schäfer ST
Thromb J; 2021 Mar; 19(1):18. PubMed ID: 33726769
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Siriez R; Dogné JM; Gosselin R; Laloy J; Mullier F; Douxfils J
Int J Lab Hematol; 2021 Feb; 43(1):7-20. PubMed ID: 32946681
[TBL] [Abstract][Full Text] [Related]
15. Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.
Vedovati MC; Mosconi MG; Isidori F; Agnelli G; Becattini C
J Thromb Thrombolysis; 2020 Feb; 49(2):251-258. PubMed ID: 31520364
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.
Brunetti L; Sanchez-Catanese B; Kagan L; Wen X; Liu M; Buckley B; Luyendyk JP; Aleksunes LM
Thromb J; 2016; 14():10. PubMed ID: 27158246
[TBL] [Abstract][Full Text] [Related]
17. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
[TBL] [Abstract][Full Text] [Related]
18. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
Maura G; Pariente A; Alla F; Billionnet C
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1367-1377. PubMed ID: 28752560
[TBL] [Abstract][Full Text] [Related]
19. Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges.
Favaloro EJ; Pasalic L; Curnow J; Lippi G
Curr Drug Metab; 2017; 18(7):598-608. PubMed ID: 28413976
[TBL] [Abstract][Full Text] [Related]
20. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).
Perlman A; Wanounou M; Goldstein R; Choshen Cohen L; Singer DE; Muszkat M
CNS Drugs; 2019 Dec; 33(12):1223-1228. PubMed ID: 31686406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
